NURS 6521 ADVANCED
PHARMACOLOGY EXAM STUDY GUIDE
QUESTIONS AND VERIFIED ANSWERS
|GRADE A+| JUST RELEASED
1. A patient with chronic kidney disease is prescribed a drug that is primarily excreted via the
kidneys. How should the clinician adjust the dosing regimen to avoid toxicity?
A. Decrease the dose or increase the dosing interval.
B. Increase the loading dose to reach steady state faster.
C. Switch to an oral route of administration to slow absorption.
D. Administer a diuretic concurrently to enhance excretion.
Answer: A
Conceptual Explanation: In renal impairment, the clearance of drugs excreted by the
kidneys is reduced, leading to higher plasma concentrations. Adjustments must involve
decreasing the dose or lengthening the interval between doses.
2. Which characteristic of a drug allows it to cross the blood-brain barrier effectively?
A. High molecular weight
,B. Highly ionized state
C. Strong binding to albumin
D. High lipid solubility
Answer: D
Conceptual Explanation: To cross the blood-brain barrier, drugs must be lipid-soluble or
utilize specific transport systems. Highly ionized or large molecules generally cannot pass
through the tight junctions of the BBB.
3. A patient is taking Warfarin and is recently started on a drug that induces the CYP2C9
enzyme. What is the most likely clinical outcome?
A. The INR will increase, increasing the risk of bleeding.
B. Warfarin toxicity will occur due to inhibited metabolism.
C. The INR will decrease, increasing the risk of thrombosis.
D. No change in INR is expected as CYP2C9 does not affect Warfarin.
Answer: C
Conceptual Explanation: CYP enzyme inducers increase the metabolism of the substrate
drug (Warfarin). Faster metabolism leads to lower drug levels and decreased therapeutic
effect, resulting in a lower INR and higher clot risk.
4. Which of the following describes the ‘First-Pass Effect’?
A. The binding of a drug to plasma proteins during its first circuit.
, B. The metabolism of an oral drug by the liver before it reaches systemic circulation.
C. The excretion of a drug by the kidneys immediately after absorption.
D. The initial rapid distribution of a drug to highly perfused organs.
Answer: B
Conceptual Explanation: The first-pass effect occurs when drugs absorbed from the GI
tract are carried to the liver via the portal vein and are extensively metabolized before
reaching the general circulation.
5. When prescribing an ACE inhibitor to a patient with heart failure, which electrolyte
abnormality is a common concern?
A. Hypokalemia
B. Hypernatremia
C. Hypocalcemia
D. Hyperkalemia
Answer: D
Conceptual Explanation: ACE inhibitors block the production of Angiotensin II, which
leads to decreased aldosterone secretion. Since aldosterone promotes potassium excretion,
its reduction leads to potassium retention (hyperkalemia).
PHARMACOLOGY EXAM STUDY GUIDE
QUESTIONS AND VERIFIED ANSWERS
|GRADE A+| JUST RELEASED
1. A patient with chronic kidney disease is prescribed a drug that is primarily excreted via the
kidneys. How should the clinician adjust the dosing regimen to avoid toxicity?
A. Decrease the dose or increase the dosing interval.
B. Increase the loading dose to reach steady state faster.
C. Switch to an oral route of administration to slow absorption.
D. Administer a diuretic concurrently to enhance excretion.
Answer: A
Conceptual Explanation: In renal impairment, the clearance of drugs excreted by the
kidneys is reduced, leading to higher plasma concentrations. Adjustments must involve
decreasing the dose or lengthening the interval between doses.
2. Which characteristic of a drug allows it to cross the blood-brain barrier effectively?
A. High molecular weight
,B. Highly ionized state
C. Strong binding to albumin
D. High lipid solubility
Answer: D
Conceptual Explanation: To cross the blood-brain barrier, drugs must be lipid-soluble or
utilize specific transport systems. Highly ionized or large molecules generally cannot pass
through the tight junctions of the BBB.
3. A patient is taking Warfarin and is recently started on a drug that induces the CYP2C9
enzyme. What is the most likely clinical outcome?
A. The INR will increase, increasing the risk of bleeding.
B. Warfarin toxicity will occur due to inhibited metabolism.
C. The INR will decrease, increasing the risk of thrombosis.
D. No change in INR is expected as CYP2C9 does not affect Warfarin.
Answer: C
Conceptual Explanation: CYP enzyme inducers increase the metabolism of the substrate
drug (Warfarin). Faster metabolism leads to lower drug levels and decreased therapeutic
effect, resulting in a lower INR and higher clot risk.
4. Which of the following describes the ‘First-Pass Effect’?
A. The binding of a drug to plasma proteins during its first circuit.
, B. The metabolism of an oral drug by the liver before it reaches systemic circulation.
C. The excretion of a drug by the kidneys immediately after absorption.
D. The initial rapid distribution of a drug to highly perfused organs.
Answer: B
Conceptual Explanation: The first-pass effect occurs when drugs absorbed from the GI
tract are carried to the liver via the portal vein and are extensively metabolized before
reaching the general circulation.
5. When prescribing an ACE inhibitor to a patient with heart failure, which electrolyte
abnormality is a common concern?
A. Hypokalemia
B. Hypernatremia
C. Hypocalcemia
D. Hyperkalemia
Answer: D
Conceptual Explanation: ACE inhibitors block the production of Angiotensin II, which
leads to decreased aldosterone secretion. Since aldosterone promotes potassium excretion,
its reduction leads to potassium retention (hyperkalemia).
